



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Zilovertamab vedotin

<b>Cat. No.:</b>	HY-P99956
<b>Target:</b>	Antibody-Drug Conjugates (ADCs); Apoptosis
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody-agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer <sup>[1]</sup> .	
<b>In Vitro</b>	Zilovertamab vedotin (VLS-101; 0-100 µg/mL) induces cytotoxicity in ROR1 <sup>+</sup> primary MCL cells in a dose-dependent manner <sup>[1]</sup> . Zilovertamab vedotin (24h; ibrutinib-sensitive (JeKo-1) and resistant (JeKo BTK KD_2) cell lines) induces cell apoptosis and cell cycle arrest at G2/M <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Zilovertamab vedotin (VLS-101; 2.5 mg/kg; i.v.; weekly, for 3 weeks) targets ROR1-expressing PDX models with dual resistance to ibrutinib and CAR T. A PDX model. Zilovertamab vedotin inhibits tumor growth <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	NSG PDX mice models with dual resistance to ibrutinib and CAR T. A PDX model <sup>[1]</sup>
	<b>Dosage:</b>	2.5 mg/kg
	<b>Administration:</b>	intravenous injection; weekly, for 3 weeks
	<b>Result:</b>	Eliminated subcutaneous tumor growth of BA-resistant PDX model (PDX-1). Prolonged tumor bearing mouse survival.

### REFERENCES

[1]. Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14(1):132.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA